Rifampin for Injection, USP, 600 mg/vial, One Vial per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S.A., NDC 67457-445-60
Published April 27, 2022 · Recall initiated: April 7, 2022
Summary
FDA records drug Class II recall D-0774-2022, published April 27, 2022 and initiated April 7, 2022. Recalling firm: Mylan Pharmaceuticals Inc; Status: Terminated; Reported quantity: 33,893 vials; Lot: Lot #: 7008990, exp. date Dec-2022; 7009025, exp. date Feb-2023; 7009085, 7009086, exp. date Apr-2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Impurities/Degradation Specifications: High out of specification results obtained for related compound during stability testing.
What to do
Voluntary: Firm initiated · Letter
Get an email if RIFAMPIN has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- RIFAMPIN
- Manufacturer
- Mylan Pharmaceuticals Inc
- Distributor
- Nationwide in the USA
- Lot
- Lot #: 7008990, exp. date Dec-2022; 7009025, exp. date Feb-2023; 7009085, 7009086, exp. date Apr-2023
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDARifampin Capsules USP, 150 mg, 30 Capsules (3 x 10) unit doses per carton, Rx Only, Distributed by: AmericanFebruary 7, 2024
- FDARifampin Capsules USP 150mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc.February 7, 2024
- FDARifampin Capsules USP 300mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc.February 7, 2024
- FDARifampin Capsules USP, 300 mg, 100 Capsules (10 x 10) per carton, Rx Only, Distributed by: American HealthJanuary 25, 2023
- FDADiclofenac Sodium Topical Solution 1.5% w/w, Generic for Pennsaid, 150 ml bottle, Rx Only, Mfg: SolaApril 27, 2022
- FDAARA-290 (Cibinetide Acetate) 6 mg/mL (4 mL) Injection, 4 mL vials, Rx only, Farmakeio 1736 N Greenville AveApril 27, 2022
Questions about this recall
Was Rifampin for Injection, USP, 600 mg/vial, One Vial per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S.A., NDC 67457-445-60 recalled?
Yes. FDA published recall D-0774-2022 on April 27, 2022. Reported hazard: Failed Impurities/Degradation Specifications: High out of specification results obtained for related compound during stability testing.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: RIFAMPIN.